4928 x 3280 px | 41,7 x 27,8 cm | 16,4 x 10,9 inches | 300dpi
Aufnahmedatum:
22. November 2019
Weitere Informationen:
Pedestrians walk past the office building of Chinese pharmaceutical company BeiGene in Suzhou Ctiy, east China's Jiangsu Province on November 22nd, 2019. A Chinese pharmaceutical company has won market approval from the United States Food and Drug Administration for a self-developed lymphoma drug, marking the first entry of an innovative cancer drug from a Chinese company into the US and giving a boost to domestic drugmakers' ambitions to create new treatments for patients around the world. The drug, known as Brukinsa, is a product from Beijing-based BeiGene. It received the FDA's approval and is expected to become available to US patients by the end of the year, Wu Xiaobin, BeiGene president, said at a news conference.
